ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Cardiovascular and Smooth Muscle Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1531361
This article is part of the Research TopicAdvancements in Transcatheter Valve Treatment: Personalized and Precision Approaches for Minimally Invasive Interventional SurgeryView all 3 articles
Multicenter Retrospective Comparison of Safety and Efficacy Among Three Antithrombotic Regimens Following TAVI
Provisionally accepted
- Zhejiang Taizhou Hospital, Taizhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This study comprehensively evaluates the safety and efficacy of three antithrombotic regimens following Transcatheter Aortic Valve Implantation (TAVI), focusing on thrombotic and bleeding complications to provide data-driven insights for optimizing postoperative management.A retrospective cohort analysis included 58 TAVI patients from two medical centers (August 2022-July 2024). Patients were assigned to three regimens post-TAVI:Group A (warfarin for 3-6 months transitioned to lifelong aspirin), Group B (warfarin transitioned to rivaroxaban), and Group C (dual antiplatelet therapy transitioned to aspirin). Key exclusion criteria were concurrent cardiac surgeries and severe hepatic or renal dysfunction. Primary outcomes included transfusion rates, bleeding incidents, and thrombotic events. Secondary outcomes included coagulation parameters (INR, PT, APTT, D-dimer) and postoperative hospital stay duration.Results: Transfusion requirements did not differ significantly across groups (p = 0.576).However, significant differences were noted in bleeding events (p = 0.034) and hospital stay duration (p < 0.001) among groups. Group B (warfarin transitioned to rivaroxaban) had the lowest bleeding incidence (0%) and the shortest hospital stay (8.71 ± 3.58 days), compared to Group A (37.5%, 14.71 ± 7.61 days) and Group C (30.0%, 7.50 ± 2.84 days). Transfusion requirements and thrombotic event rates were comparable across groups. Activated partial thromboplastin time (APTT) was significantly prolonged in Group C (p < 0.001), without corresponding clinical bleeding.Each antithrombotic regimen presented unique clinical benefits and limitations. Transitioning from warfarin to rivaroxaban was associated with a significantly reduced risk of bleeding and shorter hospital stays. Transitioning from dual antiplatelet therapy to aspirin monotherapy significant prolonged APTT without increasing clinical bleeding events. These findings highlight the importance of tailored antithrombotic strategies to optimize post-TAVI outcomes.
Keywords: TAVI, antithrombotic therapy, Dual antiplatelet therapy, Warfarin, Postoperative Complications
Received: 20 Nov 2024; Accepted: 29 May 2025.
Copyright: © 2025 Ren, Chen, Wang, Jiang and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhengli Jiang, Zhejiang Taizhou Hospital, Taizhou, China
Hua Luo, Zhejiang Taizhou Hospital, Taizhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.